Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05439200

Video Treatment for Amblyopia

The purpose of this study is to determine whether viewing asynchronous movies leads to better visual outcomes in young children with amblyopia than standard-of-care occlusion therapy with an adhesive patch and whether this is associated with better adherence to treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 year–7 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This is a single-site randomized clinical trial to compare treatment of amblyopia by viewing asynchronous movies to standard-of-care occlusion therapy with an adhesive patch. Participants will be referred from local pediatric ophthalmologists. Following informed consent, children will complete baseline testing to confirm eligibility and provide pre-treatment measurements of visual acuity, suppression, stereoacuity, motor skills, self-perception, and quality of life. Eligible children will then be randomly allocated to either patch-free occlusion therapy or standard-of-care occlusion therapy with an adhesive patch.

Children will participate in their assigned occlusion therapy at home for 6 weeks (primary outcome). Adherence will be objectively monitored. Vision will be re-assessed at 2 weeks and all tests will be repeated at 6 weeks. The asynchronous movie group will have an option to continue for and additional 2 or 4 weeks (10 weeks total). The standard-of-care occlusion group will be offered the opportunity to use the movie treatment at the 6 week visit through 10 weeks. Children who choose to remain in the study beyond the 6 week primary outcome visit will have vision reassessed at 8 and 10 weeks.

The primary analysis will be a comparison of improvement in amblyopic eye visual acuity (baseline-6 weeks) between the movie group and the standard-of-care patching group. Secondary analyses will include comparisons of adherence to each treatment, comparison of the proportion of children in each group with visual acuity ≤0.1 logMAR (recovered) at 6 weeks and 95% CIs, comparisons of changes in extent of suppression, depth of suppression, stereoacuity, motor skills standard scores, self-perception scores, and PedEyeQ domain scores. Associations among hours of treatment, changes in visual acuity, suppression, and stereoacuity, will be explored and modeled for dose-response relationships. In exploratory analyses, we will examine whether there are additional improvements in visual acuity, suppression, or stereoacuity between 6 and 10 weeks for the movie group (8 and 10 weeks means and 95% CIs).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 3-7 years
  • male and female
  • strabismic, anisometropic, or combined mechanism amblyopia (visual acuity 0.3-0.8 logMAR)
  • interocular visual acuity difference ≥0.3 logMAR
  • wearing glasses (if needed) for a minimum of 8 weeks with no change in visual acuity at 2 visits ≥4 weeks apart
  • child's ophthalmologist and family willing to forgo standard patching treatment during the study

Exclusion criteria

  • prematurity ≥8 wk
  • coexisting ocular or systemic disease
  • developmental delay
  • strabismus >5 pd
  • myopia > -3.00D

Treatment and study plan

Asynchronous 3D movies

Device

3D movies streamed at home for viewing on a handheld lenticular 3D screen

Patching

Device

Adhesive patch to cover the fellow eye

Primary outcomes

  1. Change in amblyopic eye visual acuity using a logMAR chart

    Time frame: 6 weeks

    change in amblyopic eye logMAR visual acuity relative to baseline

Secondary outcomes

  1. Change in amblyopic eye visual acuity using a logMAR chart

    Time frame: 2, 8, and 10 weeks

    change in amblyopic eye logMAR visual acuity relative to baseline at 2, 8, and 10 weeks

  2. Change in extent suppression assessed with the W4 test

    Time frame: 6 weeks

    change in log deg assessed with the W4 test relative to baseline

  3. Change in stereoacuity assessed with the Randot Preschool Stereoacuity Test

    Time frame: 6 weeks

    change in log arcsec in stereoacuity assessed with the Randot Preschool Stereoacuity Test

  4. Change in motor skills assessed with the Movement Assessment Battery for Children -2

    Time frame: 6 weeks

    change in standard scores obtained with the Movement Assessment Battery for Children -2 (MABC-2; (normed and scaled 0-19, with 10 as an average score, 5-6 as "at risk", and <5 as "significant impairment")

  5. Change in self perception assessed with the Pictorial Scale of Perceived Competence and Social Acceptance for Young Children

    Time frame: 6 weeks

    change in domain scores of the Pictorial Scale of Perceived Competence and Social Acceptance for Young Children (standard scores scaled to range from 0 to 100 for worst to best)

  6. Change in quality of life assessed with the Pediatric Eye Questionnaire

    Time frame: 6 weeks

    change in domain scores of the Pediatric Eye Questionnaire (PedEyeQ; Rasch calibrated and scaled to score from 0 to 100 for worst to best)

  7. Proportion of children who have recovered

    Time frame: 2, 6, 8, and 10 weeks

    proportion of children who attain amblyopic eye visual acuity of at least 0.1 logMAR

  8. Adherence to patching measured with a sensor and adherence to viewing videos measured with the streaming log data

    Time frame: 2,4, and 6 weeks

    cumulative hours of treatment with the patch objectively monitored temperature sensitive Theramon sensor or with movie viewing by monitoring the streaming logs

  9. Change in depth of suppression assessed with the contrast balance index

    Time frame: 6 weeks

    change in contrast balance index (ratio of amblyopic eye to fellow eye contrast needed to overcome suppression

Study contacts

Contact information is provided by the study sponsor or research team.

Eileen E Birch, PhD

CONTACT

[email protected]

2143633911 ext. 113

Reed M Jost, MS

CONTACT

[email protected]

2143633911 ext. 113

Sponsors and collaborators

Lead sponsor

Retina Foundation of the Southwest

Other

Collaborators

  • National Eye Institute (NEI)

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Jun 30, 2022
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.